Riley Bove1, Charles C White2, Kathryn C Fitzgerald2, Tanuja Chitnis2, Lori Chibnik2, Alberto Ascherio2, Kassandra L Munger2. 1. From the UCSF MS Center (R.B.), Department of Neurology, UCSF, Sandler Neurosciences Center, San Francisco, CA; Ann Romney Center for Neurologic Diseases (C.C.W., T.C., L.C.), Harvard Medical School, Boston, MA; Johns Hopkins Medical Institute (K.C.F.), Department of Neurology and Neuroimmunology, Baltimore, MD; Partners Multiple Sclerosis Center (T.C.), Department of Neurology, Brigham and Women's Hospital, Brookline; Harvard Medical School (T.C., L.C.), Boston; Channing Division of Network Medicine (A.A.), Brigham and Women's Hospital and Harvard Medical School, Boston; and Departments of Nutrition (A.A., K.L.M.) and Epidemiology (L.C., A.A.), Harvard T.H. Chan School of Public Health, Boston, MA. Riley.Bove@ucsf.edu. 2. From the UCSF MS Center (R.B.), Department of Neurology, UCSF, Sandler Neurosciences Center, San Francisco, CA; Ann Romney Center for Neurologic Diseases (C.C.W., T.C., L.C.), Harvard Medical School, Boston, MA; Johns Hopkins Medical Institute (K.C.F.), Department of Neurology and Neuroimmunology, Baltimore, MD; Partners Multiple Sclerosis Center (T.C.), Department of Neurology, Brigham and Women's Hospital, Brookline; Harvard Medical School (T.C., L.C.), Boston; Channing Division of Network Medicine (A.A.), Brigham and Women's Hospital and Harvard Medical School, Boston; and Departments of Nutrition (A.A., K.L.M.) and Epidemiology (L.C., A.A.), Harvard T.H. Chan School of Public Health, Boston, MA.
Abstract
OBJECTIVE: To determine the association between hormone therapy (HT) and physical quality of life (QOL) in postmenopausal women with multiple sclerosis (MS). METHODS: We included female participants from the prospective Nurses' Health Study, with a diagnosis of definite or probable MS, who had completed a physical functioning assessment (PF10; subscale of the 36-Item Short-Form Health Survey QOL survey) at a time point between 3 and 10 years after their final menstrual period (early postmenopause). We assessed the association between HT use at this time point (never vs at least 12 months of systemic estrogen with/without progestin) and both PF10 and the 36-Item Short-Form Health Survey Physical Component Scale. We used a linear regression model adjusting for age, MS duration, menopause type and duration, and further for additional covariates (only ancestry was significant). RESULTS: Among 95 participants meeting all inclusion criteria at their first postmenopausal assessment, 61 reported HT use and 34 reported none. HT users differed from non-HT users in MS duration (p = 0.02) and menopause type (p = 0.01) but no other clinical or demographic characteristics. HT users had average PF10 scores that were 23 points higher than non-HT users (adjusted p = 0.004) and average Physical Component Scale scores that were 9.1 points higher in the 59 women with these available (adjusted p = 0.02). Longer duration of HT use was also associated with higher PF10 scores (p = 0.02, adjusted p = 0.06). CONCLUSIONS: Systemic HT use was associated with better physical QOL in postmenopausal women with MS in this observational study. Further studies are necessary to investigate causality.
OBJECTIVE: To determine the association between hormone therapy (HT) and physical quality of life (QOL) in postmenopausal women with multiple sclerosis (MS). METHODS: We included female participants from the prospective Nurses' Health Study, with a diagnosis of definite or probable MS, who had completed a physical functioning assessment (PF10; subscale of the 36-Item Short-Form Health Survey QOL survey) at a time point between 3 and 10 years after their final menstrual period (early postmenopause). We assessed the association between HT use at this time point (never vs at least 12 months of systemic estrogen with/without progestin) and both PF10 and the 36-Item Short-Form Health Survey Physical Component Scale. We used a linear regression model adjusting for age, MS duration, menopause type and duration, and further for additional covariates (only ancestry was significant). RESULTS: Among 95 participants meeting all inclusion criteria at their first postmenopausal assessment, 61 reported HT use and 34 reported none. HT users differed from non-HT users in MS duration (p = 0.02) and menopause type (p = 0.01) but no other clinical or demographic characteristics. HT users had average PF10 scores that were 23 points higher than non-HT users (adjusted p = 0.004) and average Physical Component Scale scores that were 9.1 points higher in the 59 women with these available (adjusted p = 0.02). Longer duration of HT use was also associated with higher PF10 scores (p = 0.02, adjusted p = 0.06). CONCLUSIONS: Systemic HT use was associated with better physical QOL in postmenopausal women with MS in this observational study. Further studies are necessary to investigate causality.
Authors: M A J Visschedijk; B M J Uitdehaag; M Klein; E van der Ploeg; E H Collette; L Vleugels; L E M A Pfennings; E L J Hoogervorst; H M van der Ploeg; C H Polman Journal: Neurology Date: 2004-12-14 Impact factor: 9.910
Authors: Annet J Dallmeijer; Vincent de Groot; Leo D Roorda; Vera P M Schepers; Eline Lindeman; Leonard H van den Berg; Anita Beelen; Joost Dekker Journal: J Rehabil Med Date: 2007-03 Impact factor: 2.912
Authors: Huibo Shao; John C S Breitner; Rachel A Whitmer; Junmin Wang; Kathleen Hayden; Heidi Wengreen; Chris Corcoran; Joann Tschanz; Maria Norton; Ron Munger; Kathleen Welsh-Bohmer; Peter P Zandi Journal: Neurology Date: 2012-10-24 Impact factor: 9.910
Authors: Riley Bove; Brian C Healy; Alexander Musallam; Bonnie I Glanz; Philip L De Jager; Tanuja Chitnis Journal: Mult Scler Date: 2015-10-07 Impact factor: 6.312
Authors: Ekta Kapoor; Juliana M Kling; Angie S Lobo; Stephanie S Faubion Journal: Best Pract Res Clin Endocrinol Metab Date: 2021-09-10 Impact factor: 4.690
Authors: Riley Bove; Liene Elsone; Enrique Alvarez; Nadja Borisow; Melissa M Cortez; Farrah J Mateen; Maureen A Mealy; Kerry Mutch; Sean Tobyne; Klemens Ruprecht; Guy Buckle; Michael Levy; Dean M Wingerchuk; Friedemann Paul; Anne H Cross; Brian Weinshenker; Anu Jacob; Eric C Klawiter; Tanuja Chitnis Journal: Neurol Neuroimmunol Neuroinflamm Date: 2017-03-24
Authors: Lindsay Ross; Huah Shin Ng; Julia O'Mahony; Maria Pia Amato; Jeffrey A Cohen; Mary Pat Harnegie; Kerstin Hellwig; Mar Tintore; Sandra Vukusic; Ruth Ann Marrie Journal: Front Neurol Date: 2022-01-31 Impact factor: 4.003